View Future GrowthCanopy Growth 過去の業績過去 基準チェック /06Canopy Growthは26.3%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで8.7%毎年増加している。売上は減少しており、年平均17.9%の割合である。主要情報26.29%収益成長率40.39%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率-17.94%株主資本利益率-43.17%ネット・マージン-117.57%前回の決算情報31 Dec 2025最近の業績更新Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 07Canopy Growth Corporation to Report Q3, 2026 Results on Feb 06, 2026Jan 23Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09Canopy Growth Corporation to Report Q2, 2026 Results on Nov 07, 2025Oct 24First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 10Canopy Growth Corporation to Report Q1, 2026 Results on Aug 08, 2025Jul 25すべての更新を表示Recent updatesCanopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling Apr 23New minor risk - Insider selling Apr 04Canopy Growth Corporation Unveils Deelish Cannabis Brand With High THC At Everyday PriceMar 31Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $19.266745 million.Feb 14Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 07Canopy Growth Corporation to Report Q3, 2026 Results on Feb 06, 2026Jan 23Canopy Growth Corporation (TSX:WEED) entered into an arrangement agreement to acquire MTL Cannabis Corp. (CNSX:MTLC) for approximately CAD 120 million.Dec 15New major risk - Share price stability Dec 13Canopy Growth Corporation Launches Claybourne Gassers Liquid Diamonds All-In-One Vapes in Canada, Expanding Footprint in High-Growth Vape SegmentDec 04Canopy Growth Corporation Expands Spectrum Therapeutics Portfolio in Australia with New SoftgelsNov 19Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09Canopy Growth Corporation to Report Q2, 2026 Results on Nov 07, 2025Oct 24Canopy Growth Corporation Announces Executive AppointmentsOct 14Canopy Growth Appoints Tom Stewart as Chief Financial Officer, Effective September 17, 2025Sep 17Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $55.830365 million.Aug 30+ 1 more updateFirst quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 10Canopy Growth Corporation Appoints Margaret Shan Atkins to Its Board of Directors, Effective August 6, 2025Aug 08Canopy Growth Corporation Expands Global Medical Portfolio with Launch of 7ACRES in AustraliaAug 05Canopy Growth Corporation Announces Appointment of Miles Worne as Managing Director of European Markets, Effective August 11, 2025Jul 31Canopy Growth Corporation to Report Q1, 2026 Results on Aug 08, 2025Jul 25Canopy Growth Corporation Launches Deep Space Infused Pre-RollsJul 10Canopy Growth Corporation Appoints CFO ChangesJul 09+ 1 more updateNew minor risk - Insider selling Jul 01CFO & Principal Accounting Officer recently sold US$57k worth of stock Jun 20Full year 2025 earnings: EPS and revenues miss analyst expectations May 30New major risk - Financial position May 30Canopy Growth Corporation Drives Innovation in High-Demand Segments with Latest Product LaunchesMay 06New major risk - Share price stability Apr 23Canopy Growth: Zombie Financials As Delisting Threat Looms Apr 22Robbins LLP Informs Stockholders of the Canopy Growth Corporation Class ActionApr 05Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis BrandApr 02Cannabis Investors Should Sell Canopy Growth Mar 30Canopy Growth Corporation to Report Q4, 2025 Results on May 30, 2025Mar 19Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $250 million.Mar 01+ 1 more updateCanopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak Feb 17Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 07Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results Feb 06Canopy Growth Corporation to Report Q3, 2025 Results on Feb 07, 2025Jan 24Crashing Canopy Growth Is Still Not A Buy Jan 22New major risk - Shareholder dilution Jan 16Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty Jan 11Canopy Growth Corporation Launches Two Holiday-Inspired Cannabis Products from Tweed, Including A Sugar-Free Cranberry Ginger Ale and Tweed Snowtorious 91K FlowerDec 05Canopy Growth Corporation Appoints Luc Mongeau as Chief Executive Officer, Effective January 6, 2025Nov 26+ 1 more updateCanopy Growth Launches Claybourne Infused Pre-Rolls in CanadaNov 21Avoid Canopy Growth Nov 10Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 10Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges Oct 05Insider recently sold US$103k worth of stock Aug 27Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High Aug 27David Klein Announces to Retire as CEO of Canopy Growth CorporationAug 16First quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 11Canopy Growth Corporation to Report Q2, 2025 Results on Nov 12, 2024Aug 06Canopy Growth Corporation to Report Q1, 2025 Results on Aug 09, 2024Jul 26Canopy Growth Corporation, Annual General Meeting, Sep 24, 2024Jul 09Now 22% undervalued after recent price drop Jul 01Now 20% overvalued Jun 27Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold) Jun 17Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $250 million.Jun 08Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jun 04Canopy Growth: Another Ugly Cannabis Report Jun 03Canopy Growth Corporation to Report Q4, 2024 Results on May 30, 2024May 18New major risk - Shareholder dilution May 17Canopy Growth Set For U.S. Cannabis Markets Apr 26Less than half of directors are independent Apr 23Canopy Growth Corporation Announces Board and Committee ChangesApr 20New major risk - Share price stability Mar 23Canopy Growth Is Climbing, But It Won't Last Mar 22Canopy Growth Launches New Pre-Rolls from 7Acres and HiwayFeb 22Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 11Canopy Growth Corporation Announces Board ChangesFeb 10New major risk - Revenue and earnings growth Feb 10Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED).Feb 08Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come Feb 06Canopy Growth: Further Implosion Is Now A Matter Of When Not If Jan 29Canopy Growth Corporation Announces the Introduction of New Product Offerings Across the Company's Adult Use and Medical Cannabis PortfolioJan 24Canopy Growth Corporation announced that it expects to receive $35.000008 million in fundingJan 18Avoid Canopy Growth After Failed Equity Sale Jan 14Canopy Growth Corporation to Report Q3, 2024 Results on Feb 09, 2024Jan 13Canopy Growth Corporation announced that it expects to receive $30 million in fundingJan 09Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million.Dec 19Canopy Growth Corporation Partners with Marquee Brands Partners and Martha Stewart CBD to Unveil New Line of Need-Based CBD GummiesNov 30New minor risk - Insider selling Nov 24Canopy Growth Corporation Announces the Addition of Four New Flower Product Offerings from Iconic Brands 7ACRES and TweedNov 17New major risk - Financial position Nov 13Second quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 10Insufficient new directors Oct 01Canopy Growth Corporation announced that it expects to receive $24.99312 million in fundingSep 20Canopy Growth Corporation Announces Addition of Five New Pre-Roll Flower Product Offerings from Iconic Brands Tweed, 7ACRES, and for the First Time, from Spectrum TherapeuticsAug 23Canopy Growth Corporation Announces Executive ChangesAug 18+ 1 more updateCanopy Growth Receives Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJul 15Canopy Growth Corporation, Annual General Meeting, Sep 25, 2023Jul 08Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuit on Behalf of the Investors in Canopy Growth Corporation Who Suffered Losses from Purchasing or Otherwise Acquiring Canopy Securities Between June 1, 2021 and May 10, 2023Jul 06An unknown buyer acquired a Facility in Modesto, CA from Canopy Growth Corporation (TSX:WEED).Jun 30Canopy Growth Corporation to Report Q4, 2023 Results on Jun 22, 2023Jun 22収支内訳Canopy Growth の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:CGC 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Dec 25278-327122030 Sep 25279-387131030 Jun 25275-516137031 Mar 25269-604146031 Dec 24277-477179030 Sep 24280-586189030 Jun 24287-602196031 Mar 24297-484209031 Dec 23293-999232030 Sep 23299-991267030 Jun 23317-1,025308031 Mar 23333-3,079335031 Dec 22367-3,051401030 Sep 22423-2,938445030 Jun 22466-2,766517031 Mar 22476-255494031 Dec 21557-428588030 Sep 21569-1,223616030 Jun 21572-1,244619031 Mar 21547-1,745664031 Dec 20506-2,348765030 Sep 20477-1,535843030 Jun 20419-1,244938031 Mar 20399-1,321993031 Dec 19385-415961-530 Sep 19344-256881030 Jun 19291-832794031 Mar 19226-736642031 Dec 18155-398470430 Sep 1894-464350-130 Jun 1888-148199031 Mar 1878-67149031 Dec 1770-2195030 Sep 1758-1966130 Jun 1749-1350131 Mar 1740-839131 Dec 1630-129230 Sep 1624-725130 Jun 1618-821131 Mar 1613-317131 Dec 158013030 Sep 156111030 Jun 153-5100質の高い収益: CGCは現在利益が出ていません。利益率の向上: CGCは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CGCは利益を出していないが、過去 5 年間で年間26.3%の割合で損失を削減してきた。成長の加速: CGCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CGCは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.3% ) と比較することは困難です。株主資本利益率高いROE: CGCは現在利益が出ていないため、自己資本利益率 ( -43.17% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 08:39終値2026/05/01 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Canopy Growth Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkJesse PytlakATB Cormark Historical (Cormark Securities)20 その他のアナリストを表示
Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $19.266745 million.Feb 14
Canopy Growth Corporation (TSX:WEED) entered into an arrangement agreement to acquire MTL Cannabis Corp. (CNSX:MTLC) for approximately CAD 120 million.Dec 15
Canopy Growth Corporation Launches Claybourne Gassers Liquid Diamonds All-In-One Vapes in Canada, Expanding Footprint in High-Growth Vape SegmentDec 04
Canopy Growth Corporation Expands Spectrum Therapeutics Portfolio in Australia with New SoftgelsNov 19
Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $55.830365 million.Aug 30+ 1 more update
Canopy Growth Corporation Appoints Margaret Shan Atkins to Its Board of Directors, Effective August 6, 2025Aug 08
Canopy Growth Corporation Announces Appointment of Miles Worne as Managing Director of European Markets, Effective August 11, 2025Jul 31
Canopy Growth Corporation Drives Innovation in High-Demand Segments with Latest Product LaunchesMay 06
Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis BrandApr 02
Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $250 million.Mar 01+ 1 more update
Canopy Growth Corporation Launches Two Holiday-Inspired Cannabis Products from Tweed, Including A Sugar-Free Cranberry Ginger Ale and Tweed Snowtorious 91K FlowerDec 05
Canopy Growth Corporation Appoints Luc Mongeau as Chief Executive Officer, Effective January 6, 2025Nov 26+ 1 more update
Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED).Feb 08
Canopy Growth Corporation Announces the Introduction of New Product Offerings Across the Company's Adult Use and Medical Cannabis PortfolioJan 24
Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million.Dec 19
Canopy Growth Corporation Partners with Marquee Brands Partners and Martha Stewart CBD to Unveil New Line of Need-Based CBD GummiesNov 30
Canopy Growth Corporation Announces the Addition of Four New Flower Product Offerings from Iconic Brands 7ACRES and TweedNov 17
Canopy Growth Corporation Announces Addition of Five New Pre-Roll Flower Product Offerings from Iconic Brands Tweed, 7ACRES, and for the First Time, from Spectrum TherapeuticsAug 23
Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuit on Behalf of the Investors in Canopy Growth Corporation Who Suffered Losses from Purchasing or Otherwise Acquiring Canopy Securities Between June 1, 2021 and May 10, 2023Jul 06